13.06.2012 - A new partnership will bring GE Healthcare information on racial genetic variations in stem cells.
Chalfont St Giles/Bejing – GE Healthcare has launched a stem cell cooperation in China. Together with the Bejing Genomics Institute (BGI), the UK-based healthcare unit of the US technology major will perform a multi-year research collaboration in stem cell science. The Chinese sequencing specialist will help to explore the underlying genetic variation between ethnically diverse human stem cell lines, which may help to help advance the potential of stem cell-derived assays for use in drug discovery and toxicity testing.
GE and the BGI made the collaboration public at a special signing ceremony attended by Amr Abid, General Manager Cell Technologies at GE Healthcare Life Sciences and the three leading executives from the BGI. Two projects are planned in the frame of the cooperation. As a first project, BGI is performing genome sequencing and epigenetic analysis on cardiomyocytes and hepatocytes supplied by GE Healthcare Life Sciences. The aim is to map the genetic variation across an ethnically diverse range of stem cell lines and to examine the changes that occur during differentiation into specific cell types. As a basis for the second project, GE Healthcare will provide BGI with a IN Cell Analyzer 2000 system for high content cellular imaging analysis. The analyzer will be used by BGI to investigate gene function for a library of previously sequenced cell types by over-expressing or blocking the activity of single genes and observing the effect in selected populations of cells.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
The Development Microlute™ from Porvair Sciences is a Solid Phase Extraction (SPE) microplate which provides a wide assortment of phase chemistries and sorbent loadings in a single plate making it ideally suited for method development. more